Utilize High-Throughput Proteomics to Accelerate Hit Screening, Target Validation & Lead Optimization for Smarter & Faster Drug Development
With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable.
Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you, explore how next-generation proteomic platforms are accelerating understanding of pathology, unveiling novel drug targets, and transforming hit-to-lead development.
With a special focus on optimizing proteomics instruments to balance throughput and sensitivity, automating sample processing, unveiling hidden disease mechanisms with PTM analysis, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need.
As proteomics continues to evolve, make headlines, and revolutionize therapeutic development, unite with 70+ Directors, Vice President and Experts in Proteomics, Chemical Biology, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline.
An exceptional platform that brought together industry experts to share their experiences and discuss the latest trends and challenges in the field
Xudong Wang, Senior Scientist, Monte Rosa Therapeutics
A valuable opportunity to network with leading proteomics experts, exchange ideas across diverse research areas, and stay current on emerging technologies driving the field
Executive Director, Aethon Therapeutics
The program was well organized, and each presentation was very educational. The networking sessions were also well thought out
Senior Director, Daiichi Sankyo
Explore the Full Event Guide
- Hear from 100% brand-new speakers sharing case studies on mass spectrometry, chemoproteomics, single-cell, and spatial proteomics platforms
- Uncover drug discovery applications across bispecifics, covalent small molecules, TPD, and more
- Review real-life examples on balancing throughput, coverage, and sensitivity of proteomic workflows
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest breakthroughs in throughput, coverage, and sensitivity of proteomics methodologies, uncover data-driven presentations, and engage in panel discussions on translating large-scale proteomics data into meaningful drug discovery conclusions.
Partner With Us
Position yourself alongside other proteomics, mass spectrometry and data analysis solution providers, demonstrating your capabilities and increasing your brand awareness to a room full of proteomics decision makers.
Join Biopharma Experts
Be part of cutting-edge discussions with fellow proteomics pioneers to transform drug discovery across a range of modalities, whether you’re working on TPD, ADCs, small molecules, or beyond.